Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Winter in the Great White North -- Ignore unavailable to you. Want to Upgrade?

To: marcos who wrote (1370)	8/31/2001 11:31:46 AM
From: Rocket Red	Read Replies (1) \| Respond to of 8273

Street Rumours 0f 2000 Carats++ fot MPV Bulk Sample.

To: marcos who wrote (1370)	8/31/2001 2:45:20 PM
From: russet	Read Replies (1) \| Respond to of 8273

Feeling some hurt?? Phase 2 trials starting on the Fugu fix,...shoot 'em up and lose the pain,.... Int'l Wex gets go-ahead from government branch International Wex Technologies Inc WXI Shares issued 16,182,342 Aug 30 close $2.35 Fri 31 Aug 2001 News Release Mr. Frank Shorn reports International Wex Technologies has received its "no objection" letter from the Health Products and Food Branch (HPFB). This letter allows the company to start its phase II clinical trials immediately or as soon as all conditions to the protocol are met. Phase II will test the efficacy or effectiveness of our drug on palliative care patients with cancer pain. It will be administered on up to 36 patients. At this stage, multicentres across Canada will participate, administering various dose levels to establish the best dosing level. The resulting indicated dose level would then be used for further study on a larger number of patients on the next phase. Frank Shorn, chief executive officer, states: "We are delighted with having achieved this new level. It will be the first time that our drug is administered on patients, in North America. To date, our entire Chinese findings have been validated by our work here in Canada. This includes our preclinical animal validation studies in Canada, and the symptoms demonstrated during our extensive phase 1 clinical trials." (c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com